GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (ASX:ALA) » Definitions » Tax Provision

Arovella Therapeutics (ASX:ALA) Tax Provision : A$0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Arovella Therapeutics Tax Provision?

Arovella Therapeutics's tax provision for the six months ended in Dec. 2024 was A$0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.00 Mil.

Arovella Therapeutics Tax Provision Historical Data

The historical data trend for Arovella Therapeutics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arovella Therapeutics Tax Provision Chart

Arovella Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Arovella Therapeutics Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Arovella Therapeutics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arovella Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (ASX:ALA) » Definitions » Tax Provision
Comparable Companies
ASX:RAC ASX:PAR ASX:DXB ASX:ACW ASX:IMU ASX:LTP ASX:AGN ASX:RCE ASX:EZZ ASX:PIQ VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
E4NA:Germany
Address
84 Hotham Street, Corporate One, Preston, VIC, AUS, 3072
Website
https://www.arovella.com
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.

Arovella Therapeutics Headlines

No Headlines